RxDoctor Payments Data

Martha Ellis, PA

Medical · Phoenix, AZNPI 1568483006

Payments from drug & device makers

$1,255in general payments, 2019–2025

Across 51 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intra-sana Laboratories$250
  • Lilly USA, LLC$244
  • Novo Nordisk$237
  • Lucid Diagnostics Inc.$92
  • Abbott$56
  • Exact Sciences$50
  • plus $327 from 13 others

What the payments were for

  • Food & beverage$1,255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,255 in reported general payments places this provider in the 60th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$13,839
Medicare patients
73
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$54,950
MounjaroTirzepatide23$27,922
WegovySemaglutide17$22,304
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$659
Rosuvastatin Calcium45$579
Levothyroxine Sodium45$383
Losartan Potassium31$272
Tamsulosin Hcl13$256
Montelukast Sodium11$212
Omeprazole18$211
Metoprolol Succinate11$165
Temazepam11$165
Atorvastatin Calcium17$153
Sertraline Hcl16$150
Trazodone Hcl29$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$237$77,25454 claims
Lilly USA, LLCMounjaro$244$27,92223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 748 medical providers in Arizona.

Other medical in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →